FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Wayne Border

Research Profile

Chemicals & Drugs

Living Beings

Disorders

Anatomy

Physiology

Gene Expression

Co-author Network

Publications

TOP 3
Yufeng Huang; Wayne A Border; Daniel Lawrence; Nancy A Noble
Mechanisms underlying the antifibrotic properties of noninhibitory PAI-1 (PAI-1R) in experimental nephritis.
jiandong Zhang; Nancy A Noble; Wayne A Border; Rick T Owens; Yufeng Huang
Receptor-dependent prorenin activation and induction of PAI-1 expression in vascular smooth muscle cells.
Wei Huang; Chen Xu; Kyoung W Kahng; Nancy A Noble; Wayne A Border; Yufeng Huang
Aldosterone and TGF-beta1 synergistically increase PAI-1 and decrease matrix degradation in rat renal mesangial and fibroblast cells.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Wayne Border (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2009: Yufeng Huang; Wayne A Border; Daniel Lawrence; Nancy A Noble
Mechanisms underlying the antifibrotic properties of noninhibitory PAI-1 (PAI-1R) in experimental nephritis.
American journal of physiology. Renal physiology 2009;297(4):F1045-54.
2008: jiandong Zhang; Nancy A Noble; Wayne A Border; Rick T Owens; Yufeng Huang
Receptor-dependent prorenin activation and induction of PAI-1 expression in vascular smooth muscle cells.
American journal of physiology. Endocrinology and metabolism 2008;295(4):E810-9.
2008: Wei Huang; Chen Xu; Kyoung W Kahng; Nancy A Noble; Wayne A Border; Yufeng Huang
Aldosterone and TGF-beta1 synergistically increase PAI-1 and decrease matrix degradation in rat renal mesangial and fibroblast cells.
American journal of physiology. Renal physiology 2008;294(6):F1287-95.
2008: Yufeng Huang; Wayne A Border; Ling Yu; jiandong Zhang; Daniel Lawrence; Nancy A Noble
A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy.
Journal of the American Society of Nephrology : JASN 2008;19(2):329-38.
2007: Yufeng Huang; Nancy A Noble; jiandong Zhang; C Xu; Wayne A Border
Renin-stimulated TGF-beta1 expression is regulated by a mitogen-activated protein kinase in mesangial cells.
Kidney international 2007;72(1):45-52.
2007: Yufeng Huang; Wayne A Border; Nancy A Noble
Functional renin receptors in renal mesangial cells.
Current hypertension reports 2007;9(2):133-9.
2006: Yufeng Huang; Wayne A Border; Daniel Lawrence; Nancy A Noble
Noninhibitory PAI-1 enhances plasmin-mediated matrix degradation both in vitro and in experimental nephritis.
Kidney international 2006;70(3):515-22.
2006: Yufeng Huang; Wayne A Border; Nancy A Noble
Perspectives on blockade of TGFbeta overexpression.
Kidney international 2006;69(10):1713-4.
2006: Yufeng Huang; S Wongamorntham; J Kasting; David J McQuillan; R T Owens; Ling Yu; Nancy A Noble; Wayne A Border
Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms.
Kidney international 2006;69(1):105-13.
2005: Jens Gaedeke; Nancy A Noble; Wayne A Border
Curcumin blocks fibrosis in anti-Thy 1 glomerulonephritis through up-regulation of heme oxygenase 1.
Kidney international 2005;68(5):2042-9.
2004: Ling Yu; Wayne A Border; Ian Kevin Anderson; Matthew McCourt; Yufeng Huang; Nancy A Noble
Combining TGF-beta inhibition and angiotensin II blockade results in enhanced antifibrotic effect.
Kidney international 2004;66(5):1774-84.
2004: Jens Gaedeke; Nancy A Noble; Wayne A Border
Curcumin blocks multiple sites of the TGF-beta signaling cascade in renal cells.
Kidney international 2004;66(1):112-20.
2003: Joris A Aben; Dennis A Hoogervorst; Leendert C Paul; Maria C Borrias; Nancy A Noble; Wayne A Border; Jan A Bruijn; Emile de Heer
Genes expressed by the kidney, but not by bone marrow-derived cells, underlie the genetic predisposition to progressive glomerulosclerosis after mesangial injury.
Journal of the American Society of Nephrology : JASN 2003;14(9):2264-70.
2003: Ling Yu; Wayne A Border; Yufeng Huang; Nancy A Noble
TGF-beta isoforms in renal fibrogenesis.
Kidney international 2003;64(3):844-56.
2003: Yufeng Huang; Masashi Haraguchi; Daniel Lawrence; Wayne A Border; Ling Yu; Nancy A Noble
A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis.
The Journal of clinical investigation 2003;112(3):379-88.
2003: Harm Peters; Wayne A Border; Matthias Rückert; Stephanie Krämer; Hans-Hellmut Neumayer; Nancy A Noble
L-arginine supplementation accelerates renal fibrosis and shortens life span in experimental lupus nephritis.
Kidney international 2003;63(4):1382-92.
2002: Jens Gaedeke; Nancy A Noble; Wayne A Border
Angiotensin II and progressive renal insufficiency.
Current hypertension reports 2002;4(5):403-7.
2002: Ling Yu; Nancy A Noble; Wayne A Border
Therapeutic strategies to halt renal fibrosis.
Current opinion in pharmacology 2002;2(2):177-81.
2001: Wayne A Border; Nancy A Noble
Maximizing hemodynamic-independent effects of angiotensin II antagonists in fibrotic diseases.
Seminars in nephrology 2001;21(6):563-72.
2001: M Haraguchi; Wayne A Border; Yufeng Huang; Nancy A Noble
t-PA promotes glomerular plasmin generation and matrix degradation in experimental glomerulonephritis.
Kidney international 2001;59(6):2146-55.
2001: Jens Gaedeke; H Peters; Nancy A Noble; Wayne A Border
Angiotensin II, TGF-beta and renal fibrosis.
Contributions to nephrology 2001;(135):153-60.
2000: H Peters; Wayne A Border; Nancy A Noble
Angiotensin II blockade and low-protein diet produce additive therapeutic effects in experimental glomerulonephritis.
Kidney international 2000;57(4):1493-501.
2000: Wayne A Border; Nancy A Noble
Effect of maximal reduction of angiotensin in renal fibrosis: bad news-good news from a pediatric mouse.
American journal of kidney diseases : the official journal of the National Kidney Foundation 2000;35(4):773-6.
2000: H Peters; Wayne A Border; Nancy A Noble
Tandem antifibrotic actions of L-arginine supplementation and low protein diet during the repair phase of experimental glomerulonephritis.
Kidney international 2000;57(3):992-1001.
1999: H Peters; Wayne A Border; Nancy A Noble
From rats to man: a perspective on dietary L-arginine supplementation in human renal disease.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 1999;14(7):1640-50.
1999: H Peters; Wayne A Border; Nancy A Noble
L-Arginine supplementation increases mesangial cell injury and subsequent tissue fibrosis in experimental glomerulonephritis.
Kidney international 1999;55(6):2264-73.
1999: T Yamamoto; Nancy A Noble; D E Miller; L I Gold; A Hishida; M Nagase; A H Cohen; Wayne A Border
Increased levels of transforming growth factor-beta in HIV-associated nephropathy.
Kidney international 1999;55(2):579-92.
1999: Yoshitaka Isaka; Yoshitaka Akagi; Y Ando; M Tsujie; T Sudo; N Ohno; Wayne A Border; Nancy A Noble; Yasufumi Kaneda; Masatsugu Hori; Enyu Imai
Gene therapy by transforming growth factor-beta receptor-IgG Fc chimera suppressed extracellular matrix accumulation in experimental glomerulonephritis.
Kidney international 1999;55(2):465-75.
1999: H Peters; Wayne A Border; Nancy A Noble
Targeting TGF-beta overexpression: maximizing the antifibrotic actions of angiotensin II blockade in anti-Thy1 glomerulonephritis.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 1999;14 Suppl 4():22-3.
1998: H Peters; Wayne A Border; Nancy A Noble
Targeting TGF-beta overexpression in renal disease: maximizing the antifibrotic action of angiotensin II blockade.
Kidney international 1998;54(5):1570-80.
1998: Wayne A Border; Nancy A Noble
Evidence that TGF-beta should be a therapeutic target in diabetic nephropathy.
Kidney international 1998;54(4):1390-1.
1998: Wayne A Border; Nancy A Noble
Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis.
Hypertension 1998;31(1 Pt 2):181-8.
1997: Nancy A Noble; Wayne A Border
Angiotensin II in renal fibrosis: should TGF-beta rather than blood pressure be the therapeutic target?
Seminars in nephrology 1997;17(5):455-66.
1997: H Peters; Nancy A Noble; Wayne A Border
Transforming growth factor-beta in human glomerular injury.
Current opinion in nephrology and hypertension 1997;6(4):389-93.
1997: Wayne A Border; Nancy A Noble
TGF-beta in kidney fibrosis: a target for gene therapy.
Kidney international 1997;51(5):1388-96.
1997: Shoji Kagami; T Kuhara; K Okada; Yasuhiro Kuroda; Wayne A Border; Nancy A Noble
Dual effects of angiotensin II on the plasminogen/plasmin system in rat mesangial cells.
Kidney international 1997;51(3):664-71.
1996: M Ketteler; N Ikegaya; D K Brees; Wayne A Border; Nancy A Noble
L-arginine metabolism in immune-mediated glomerulonephritis in the rat.
American journal of kidney diseases : the official journal of the National Kidney Foundation 1996;28(6):878-87.
1996: Fuad S Shihab; Takeshi F Andoh; AM Tanner; Nancy A Noble; Wayne A Border; Nora Franceschini; William M Bennett
Role of transforming growth factor-beta 1 in experimental chronic cyclosporine nephropathy.
Kidney international 1996;49(4):1141-51.
1996: Y Isaka; D K Brees; K Ikegaya; Y Kaneda; E Imai; Nancy A Noble; Wayne A Border
Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney.
Nature medicine 1996;2(4):418-23.
1996: T Yamamoto; Nancy A Noble; A H Cohen; C C Nast; A Hishida; L I Gold; Wayne A Border
Expression of transforming growth factor-beta isoforms in human glomerular diseases.
Kidney international 1996;49(2):461-9.
1995: Wayne A Border; Nancy A Noble
Targeting TGF-beta for treatment of disease.
Nature medicine 1995;1(10):1000-1.
1995: Fuad S Shihab; T Yamamoto; C C Nast; A H Cohen; Nancy A Noble; L I Gold; Wayne A Border
Transforming growth factor-beta and matrix protein expression in acute and chronic rejection of human renal allografts.
Journal of the American Society of Nephrology : JASN 1995;6(2):286-94.
1995: Wayne A Border; Nancy A Noble; M Ketteler
TGF-beta: a cytokine mediator of glomerulosclerosis and a target for therapeutic intervention.
Kidney international. Supplement 1995;49():S59-61.
1995: I Narita; Wayne A Border; M Ketteler; E Ruoslahti; Nancy A Noble
L-arginine may mediate the therapeutic effects of low protein diets.
Proceedings of the National Academy of Sciences of the United States of America 1995;92(10):4552-6.
1995: I Narita; Wayne A Border; M Ketteler; Nancy A Noble
Nitric oxide mediates immunologic injury to kidney mesangium in experimental glomerulonephritis.
Laboratory investigation; a journal of technical methods and pathology 1995;72(1):17-24.
1995: M Ketteler; Nancy A Noble; Wayne A Border
Transforming growth factor-beta and angiotensin II: the missing link from glomerular hyperfiltration to glomerulosclerosis?
Annual review of physiology 1995;57():279-95.
1994: M Ketteler; Nancy A Noble; Wayne A Border
Increased expression of transforming growth factor-beta in renal disease.
Current opinion in nephrology and hypertension 1994;3(4):446-52.
1994: Shoji Kagami; Wayne A Border; D E Miller; Nancy A Noble
Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells.
The Journal of clinical investigation 1994;93(6):2431-7.
1994: T Yamamoto; Nancy A Noble; D E Miller; Wayne A Border
Sustained expression of TGF-beta 1 underlies development of progressive kidney fibrosis.
Kidney international 1994;45(3):916-27.
1994: E Ruoslahti; Nancy A Noble; Shoji Kagami; Wayne A Border
Integrins.
Kidney international. Supplement 1994;44():S17-22.
1994: Wayne A Border; D Brees; Nancy A Noble
Transforming growth factor-beta and extracellular matrix deposition in the kidney.
Contributions to nephrology 1994;107():140-5.
1994: Wayne A Border
Transforming growth factor-beta and the pathogenesis of glomerular diseases.
Current opinion in nephrology and hypertension 1994;3(1):54-8.
1993: Shoji Kagami; Wayne A Border; E Ruoslahti; Nancy A Noble
Coordinated expression of beta 1 integrins and transforming growth factor-beta-induced matrix proteins in glomerulonephritis.
Laboratory investigation; a journal of technical methods and pathology 1993;69(1):68-76.
1993: Wayne A Border; Nancy A Noble
Cytokines in kidney disease: the role of transforming growth factor-beta.
American journal of kidney diseases : the official journal of the National Kidney Foundation 1993;22(1):105-13.
1993: T Yamamoto; T Nakamura; Nancy A Noble; E Ruoslahti; Wayne A Border
Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy.
Proceedings of the National Academy of Sciences of the United States of America 1993;90(5):1814-8.
1992: S Tomooka; Wayne A Border; Bruce C Marshall; Nancy A Noble
Glomerular matrix accumulation is linked to inhibition of the plasmin protease system.
Kidney international 1992;42(6):1462-9.
1992: Wayne A Border; Nancy A Noble; T Yamamoto; J R Harper; Y u Yamaguchi; M D Pierschbacher; E Ruoslahti
Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease.
Nature 1992;360(6402):361-4.
1992: D E Miller; Nancy A Noble; X Yu; Wayne A Border
Molecular and cellular biological techniques in the study of glomerular diseases.
Seminars in nephrology 1992;12(6):506-15.
1992: Wayne A Border; E Ruoslahti
Transforming growth factor-beta in disease: the dark side of tissue repair.
The Journal of clinical investigation 1992;90(1):1-7.
1992: T Nakamura; D Miller; E Ruoslahti; Wayne A Border
Production of extracellular matrix by glomerular epithelial cells is regulated by transforming growth factor-beta 1.
Kidney international 1992;41(5):1213-21.
1992: Wayne A Border; Nancy A Noble; T Yamamoto; S Tomooka; Shoji Kagami
Antagonists of transforming growth factor-beta: a novel approach to treatment of glomerulonephritis and prevention of glomerulosclerosis.
Kidney international 1992;41(3):566-70.
1992: Nancy A Noble; J R Harper; Wayne A Border
In vivo interactions of TGF-beta and extracellular matrix.
Progress in growth factor research 1992;4(4):369-82.
1991: S Okuda; T Nakamura; T Yamamoto; E Ruoslahti; Wayne A Border
Dietary protein restriction rapidly reduces transforming growth factor beta 1 expression in experimental glomerulonephritis.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(21):9765-9.
1991: Wayne A Border; S Okuda; T Nakamura; L R Languino; E Ruoslahti
Role of TGF-beta 1 in experimental glomerulonephritis.
Ciba Foundation symposium 1991;157():178-89; discussion 189-93.
1990: Wayne A Border; E Ruoslahti
Transforming growth factor-beta 1 induces extracellular matrix formation in glomerulonephritis.
Cell differentiation and development : the official journal of the International Society of Developmental Biologists 1990;32(3):425-31.
1990: S Okuda; L R Languino; E Ruoslahti; Wayne A Border
Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis. Possible role in expansion of the mesangial extracellular matrix.
The Journal of clinical investigation 1990;86(2):453-62.
1990: Wayne A Border; S Okuda; L R Languino; Michael B. Sporn; E Ruoslahti
Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1.
Nature 1990;346(6282):371-4.
1990: G N Marinides; G C Groggel; A H Cohen; Wayne A Border
Enalapril and low protein reverse chronic puromycin aminonucleoside nephropathy.
Kidney international 1990;37(2):749-57.
1990: Wayne A Border; S Okuda; L R Languino; E Ruoslahti
Transforming growth factor-beta regulates production of proteoglycans by mesangial cells.
Kidney international 1990;37(2):689-95.
1989: Wayne A Border; S Okuda; T Nakamura
Extracellular matrix and glomerular disease.
Seminars in nephrology 1989;9(4):307-17.
1988: Wayne A Border
Distinguishing minimal-change disease from mesangial disorders.
Kidney international 1988;34(3):419-34.
1988: G C Groggel; J Stevenson; P Hovingh; A Linker; Wayne A Border
Changes in heparan sulfate correlate with increased glomerular permeability.
Kidney international 1988;33(2):517-23.
1987: G N Marinides; G C Groggel; A H Cohen; T Cook; R L Baranowski; Christof Westenfelder; Wayne A Border
Failure of angiotensin converting enzyme inhibition to affect the course of chronic puromycin aminonucleoside nephropathy.
The American journal of pathology 1987;129(2):394-401.
1987: G C Groggel; P Hovingh; Wayne A Border; A Linker
Changes in glomerular heparan sulfate in puromycin aminonucleoside nephrosis.
The American journal of pathology 1987;128(3):521-7.
1987: G C Groggel; Wayne A Border; Christof Westenfelder
The kidney in hypergammaglobulinemic purpura.
American journal of kidney diseases : the official journal of the National Kidney Foundation 1987;9(2):172-5.